Method of treating inflammation
Inventors
Chan, Phillip P. • Young, Wei-Tai • Capponi, Vincent J. • Golobish, Thomas D. • Ali, Humayra Begum
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-10946040-B2
Publication Date
2021-03-16
Expiration Date
Abstract
The present invention concerns methods of administering a therapeutically effective dose of a sorbent for an inflammatory mediator to a patient where the inflammatory mediator is one or more of enzymes, cytokines, prostaglandins, eicosanoids, leukotrienes, kinins, complement, coagulation factors, endotoxins, enterotoxins, lipopolysaccharide, cell fragments, bile salts, fatty acids, phospholipids, interferon and immunomodulatory antibodies, biologics or drugs.
Core Innovation
The invention provides a method of treating inflammation in a patient by administering a therapeutically effective dose of a sorbent that sequesters an inflammatory mediator. The sorbent is a biocompatible polymer, and the inflammatory mediator is identified as a cytokine resulting from inflammatory bowel disease, burns, sepsis, or exposure of the patient to neurotoxins.
The biocompatible polymer is defined by monomer-derived residues selected from divinylbenzene, ethylvinylbezene, styrene, ethylstyrene, and mixtures thereof. The polymer has a pore structure such that the total pore volume of pore size in the range of 50 Å to 3000 Å is greater than 0.5 cc/g to 3.0 cc/g dry polymer.
The invention further includes a pharmaceutical kit configuration that provides a therapeutically effective dose of the same biocompatible polymer sorbent for treating inflammation. The kit recites the same biocompatible polymer composition and pore-structure total pore volume range, and the same inflammatory mediator scope and administration routes.
Claims Coverage
The provided content includes two independent claims. The claims cover administering a therapeutically effective dose of a biocompatible polymer sorbent with defined monomer composition and defined pore-volume range to treat inflammation associated with specific inflammatory mediator contexts, and a pharmaceutical kit presentation of the same sorbent.
Biocompatible polymer sorbent with defined monomer residues and pore-volume threshold for inflammation treatment
A method of treating inflammation by administering a therapeutically effective dose of a sorbent for an inflammatory mediator, where the sorbent is a biocompatible polymer comprising residues from one or more monomers selected from divinylbenzene, ethylvinylbezene, styrene, ethylstyrene, and mixtures thereof, and having a pore structure such that the total pore volume of pore size in the range of 50 Å to 3000 Å is greater than 0.5 cc/g to 3.0 cc/g dry polymer.
Administration routes and inflammatory mediator scope for biocompatible polymer sorbent therapy
The sorbent is administered orally, via a feeding tube, peritoneally, or rectally, and the inflammatory mediator is a cytokine resulting from inflammatory bowel disease in the patient, burns to the patient, sepsis in the patient, or exposure of the patient to neurotoxins.
Pharmaceutical kit for administering biocompatible polymer sorbent with defined monomer residues and pore-volume threshold
A pharmaceutical kit comprising a therapeutically effective dose of a sorbent for an inflammatory mediator, where the sorbent is a biocompatible polymer comprising residues from one or more monomers selected from divinylbenzene, ethylvinylbezene, styrene, ethylstyrene, and mixtures thereof, and having a pore structure such that the total pore volume of pore size in the range of 50 Å to 3000 Å is greater than 0.5 cc/g to 3.0 cc/g dry polymer.
Kit-covered administration routes and inflammatory mediator scope
In the kit, the sorbent is administered orally, via a feeding tube, peritoneally, or rectally, and the inflammatory mediator is a cytokine resulting from inflammatory bowel disease in the patient, burns to the patient, sepsis in the patient, or exposure of the patient to neurotoxins.
The inventive coverage centers on treating inflammation by administering a therapeutically effective dose of a biocompatible polymer sorbent defined by specified monomer-derived residues and a defined pore-structure total pore-volume range, with administration via oral, feeding tube, peritoneal, or rectal routes, and with a cytokine associated with inflammatory bowel disease, burns, sepsis, or neurotoxin exposure; a second independent claim additionally covers a pharmaceutical kit providing this sorbent dose.
Stated Advantages
Documented Applications
Treating inflammation in a patient where the inflammatory mediator is a cytokine resulting from inflammatory bowel disease, burns, or sepsis, or exposure of the patient to neurotoxins.
Administration of the biocompatible polymer sorbent orally, via feeding tube, peritoneally, or rectally.
Interested in licensing this patent?